Stock VXL VAXIL BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vaxil Bio Ltd.

Equities

VXL

CA92243L1076

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:10:23 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.015 CAD +50.00% Intraday chart for Vaxil Bio Ltd. 0.00% -40.00%
Mar. 04 Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. in a reverse merger transaction. CI
Jan. 10 Vaxil Bio Entered Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 3.291 2.668 3.113 34.74 10.27 2.74
Enterprise Value (EV) 1 3.2 1.964 3.148 33.24 8.032 1.23
P/E ratio -1.82 x -2.44 x -2.7 x -22.5 x -10.4 x -4.69 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -1.82 x -1.99 x -2.85 x -24.8 x -8.31 x -2.11 x
EV / FCF -7.55 x -2.26 x -18.8 x -55 x -11.4 x -2.39 x
FCF Yield -13.2% -44.2% -5.31% -1.82% -8.74% -41.9%
Price to Book -6.76 x 6.13 x -5.34 x 44.3 x 6.04 x 2.41 x
Nbr of stocks (in thousands) 50,624 88,929 88,929 115,809 136,979 136,979
Reference price 2 0.0650 0.0300 0.0350 0.3000 0.0750 0.0200
Announcement Date 4/30/18 4/23/19 4/27/20 4/29/21 4/29/22 4/27/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -1.756 -0.985 -1.106 -1.343 -0.967 -0.582
EBIT 1 -1.803 -1.041 -1.143 -1.347 -0.986 -0.584
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -1.798 -1.047 -1.154 -1.358 -0.986 -0.584
Net income 1 -1.798 -1.047 -1.154 -1.358 -0.986 -0.584
Net margin - - - - - -
EPS 2 -0.0357 -0.0123 -0.0130 -0.0133 -0.007244 -0.004263
Free Cash Flow 1 -0.4239 -0.8684 -0.1672 -0.6048 -0.7022 -0.515
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/18 4/23/19 4/27/20 4/29/21 4/29/22 4/27/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - 0.04 - - -
Net Cash position 1 0.09 0.7 - 1.5 2.24 1.51
Leverage (Debt/EBITDA) - - -0.0316 x - - -
Free Cash Flow 1 -0.42 -0.87 -0.17 -0.6 -0.7 -0.52
ROE (net income / shareholders' equity) -2,128% 4,027% 1,559% -1,229% -78.8% -41.2%
ROA (Net income/ Total Assets) -148% -108% -130% -90.2% -31.2% -19.1%
Assets 1 1.218 0.9655 0.8844 1.505 3.157 3.061
Book Value Per Share 2 -0.0100 0 -0.0100 0.0100 0.0100 0.0100
Cash Flow per Share 2 0 0.0100 0 0.0100 0.0200 0.0100
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/30/18 4/23/19 4/27/20 4/29/21 4/29/22 4/27/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VAXIL BIO LTD. Stock Vaxil Bio Ltd.
-40.00% 1.5M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VXL Stock
  4. Financials Vaxil Bio Ltd.